

Special Issue

Vaccine, Preventive Strategies and Antiviral Responses to Zoonotic Viruses

Message from the Guest Editors

We are now facing a world increasingly affected by viral zoonoses entering the human society. Vaccines remain the top priority for preventing infectious diseases, yet many viral zoonotic pathogens, especially emerging ones, lack licensed vaccines. This Special Issue aims to publish recent progress on vaccine development and efficacy evaluation, immune responses and immunologic mechanisms, as well as development of animal models against various zoonotic viral pathogens. Those include numerous viral pathogens that are characterized by different taxonomic categories, including Alphavirus, Arenavirus, Bunyavirus, Coronavirus, Flavivirus, Filovirus, Orthopoxvirus, Orthomyxovirus, Paramyxovirus, Rhabdovirus, etc. For this Special Issue, research areas may include (but are not limited to) the following areas:

- Animal models for viral zoonoses;
- Vaccine development and efficacy evaluation for viral zoonoses;
- Immune responses to vaccines and the underlying immunologic mechanisms;
- Adjuvants and immunomodulators for vaccines;
- Next-generation vaccine technology;
- Clinical trials of vaccines;
- Epidemiology and significance of viral mutation for vaccine efficacy.

Guest Editors

Dr. Wei Ye

Dr. Shu Shen

Prof. Dr. Chen Peng

Dr. Ben Hu

Deadline for manuscript submissions

31 May 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/211387

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).